JINLING PHARM.(SZ:000919) Xin Lang Cai Jing·2025-08-28 02:30Core Insights - Jinling Pharmaceutical (000919.SZ) reported a total operating revenue of 1.601 billion yuan for the first half of 2025, ranking 32nd among disclosed peers, which represents a decrease of 113 million yuan or 6.62% year-on-year [1] - The net profit attributable to shareholders was 48.33 million yuan, ranking 65th among peers, down by 7.92 million yuan or 14.08% compared to the same period last year [1] - The net cash inflow from operating activities was 15.84 million yuan, ranking 91st among peers, a decrease of 5.52 million yuan or 25.82% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 20.34%, ranking 45th among peers, an increase of 0.79 percentage points from the previous quarter and 3.73 percentage points from the same period last year [3] - The latest gross profit margin is 19.43%, ranking 113th among peers, with a slight increase of 0.07 percentage points from the previous quarter but a decrease of 1.54 percentage points year-on-year [3] - The latest return on equity (ROE) is 1.28%, ranking 84th among peers, down by 0.09 percentage points compared to the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is 0.08 yuan, ranking 77th among peers, a decrease of 0.02 yuan or 21.59% year-on-year [3] - The latest total asset turnover ratio is 0.26 times, ranking 35th among peers, a decrease of 0.02 times year-on-year [3] - The latest inventory turnover ratio is 5.02 times, ranking 1st among peers, an increase of 0.56 times or 12.49% year-on-year [3] Shareholder Structure - The number of shareholders is 35,400, with the top ten shareholders holding 322 million shares, accounting for 51.58% of the total share capital [3] - The largest shareholder is Nanjing New Industry Investment Group Co., Ltd., holding 41.59% of the shares [3]